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Abstract
BACKGROUND: Systemic lupus erythematosus (SLE) disease is characterized by a loss of self-tolerance leading to 
a local tissue inflammation up to a massive systemic organ-spesific inflammation. Mesenchymal stem cells (MSCs) 
present immunomodulatory properties to control the over-activating immune responses in SLE through several 
mechanisms. However, the capability of MSCs to decrease interleukin (IL)-12 production in in vitro remains unclear.
AIM: The aim of this study was to investigate the role of MSCs in decreasing the level of IL-12 derived from peripheral 
blood mononuclear cells (PBMCs) of SLE patients.
METHODS: This study used a post-test control group design using a coculture of PBMCs from SLE and healthy 
patients with MSCs as the subjects. This study included five groups: sham (Sh), control (C), and treatment groups 
(T) treated by a co-culture MSCs with PBMCs at ratio dose of 1:1 (T1), 1:25 (T2), and 1:50 (T3), respectively, for 72 
hours of incubation. The IL-12 levels was analysed by cytometric bead array (CBA) of flow cytometry.
RESULTS: This study showed a significant decrease of IL-12 levels (p < 0.05) in T1 and T2 after 72 hours incubation 
of co-culture MSCs with PBMCs from SLE patient.
CONCLUSION: MSCs could decrease the level of IL-12 in PBMCs of human SLE to control the inflammation of 
SLE disease.
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Introduction
Systemic lupus erythematosus (SLE) is a highly 
complex and heterogeneous autoimmune disease 
characterized by a loss of the immune response tolerance 
to self-antigens that induce an excessive generation of 
autoantibodies against, immune complex formation, 
triggering systemic organ-specific inflammation [1]. 
The host immune responses to these autoantibody-
autoantigen complexes depositing into various tissues 
of the body including renal tissues induce a local 
inflammatory response up to severe tissue destructions 
such as lupus nephritis (LN) to renal failure [2]. The 
persistent risk enhancement of these organ failures' 
SLE patients mortality trend, making SLE treatment 
by controlling the initial inflammation processes, is a 
challenge [3]. On the other hand, interleukin 12 (IL-12) 
was involved in the LN development by inducing the 
T-cells to actively release the inflammatory mediators, 
thus decreasing the IL-12 level associated with LN's 
immprovement in the SLE diseases [4]. Mesenchymal 
stem cells (MSCs) have a robust immunosupressive 
capability to inflammatory cells, and therefore, the 
MSCs was assumed to be potentially controlling the 
initial f SLE by suppressing IL-12. [5].
Mesenchymal stem cells (MSCs) represent a 
heterogeneous population of fibroblast-like multipotent 
cells derived from various sources, including umbilical 
cord (UC), bone marrow, dental pulp, and adipose 
tissues. These cells have the ability to differentiate into 
tissues of mesodermal lineage and are characterized 
by the high expression of several surface antigens, 
such as CD90, CD105, CD44, and CD73, and lack 
of expression of CD79 or CD19, CD14 or CD11b, 
CD45, CD34, and HLA-DR [5]. Nowadays, MSC 
populations are being extensively investigated for 
their immunomodulatory properties. A previous study 
reported that MSC transplantation had a therapeutic 
effect on various autoimmune diseases, including 
SLE. The one reasoning use of MSCs to SLE studies 
is their ability to hamper an excessive inflammation 
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by enhancing the regulatory lymphocyte cells (Treg) 
modulation [7,8]. The functional Treg can release 
several anti-inflammatory cytokines that to inhibit the 
autoreactive T cells including T helper 1 (Th1) cell 
activation by downregulation of IL-12 [5], [9].
As one of the pro-inflammatory cytokines 
released by antigen-presenting cells (APCs), such 
as macrophages and dendritic cells (DCs), IL-12 is 
responsible for mediating adaptive immune response, 
particularly Th1 cells [10]. Several studies have reported 
that the overexpression of IL-12 in SLE diseases can 
massively induce the differentiation of naive Th into Th1 
cells leading to the inflammatory niche formation in renal, 
known as the LN disease [11,12]. On the other hand, a 
recent study also revealed that MSCs have the suppressive 
capability to control several autoimmune cells, including in 
SLE diseases, by enhancing the functionality of the Treg 
subset [13]. The activation of functional Treg along with 
MSCs can suppress the most inflammatory cells including 
in releasing IL-12 on APCs mechanism resulting in the 
decrease of the naïve CD4 Th differentiation to Th1 that 
is correlated with the the improvement of inflammatory 
tissues [14], [15], [16]. However, capability of human 
MSCs to decrease IL-12 production in peripheral blood 
mononuclear cells (PBMCs) from SLE patients in vitro 
remains unclear. Hence, this study we investigated to the 
role of MSCs in decreasing the level of IL-12 derived from 
PBMCs of SLE patients in vitro.
Materials and Methods
Lupus patients and healthy subjects
This study was conducted in the Stem Cell 
and Cancer Research (SCCR) Laboratory, Faculty of 
Medicine, Sultan Agung Islamic University, Semarang, 
in September-October 2019. In total, 20 SLE patients 
from Kariadi Hospital and 5 healthy subjects were 
included in this study. Specific informed consent 
was obtained from each subject for peripheral blood 
and UC collection. This study was approved by and 
conducted in accordance with the review board of the 
Health Research Ethical Committee Medical Faculty of 
Universitas Sumatera Utara (USU), Medan, under No. 
698/TGL/KEPK FK USU-RSUP HAM/2019.
The participants were divided into five groups: 
Negative and positive control groups were treated with 
standard medium, and the treatment group was cocultured 
with human UC-MSC at doses of 1:1, 1:25, and 1:50 
(MSCs:peripheral blood mononuclear cells [PBMCs]).
MSC isolation
MSCs were isolated from fresh Wharton jelly 
of the UC obtained from healthy mothers in the local 
maternity hospital with specific informed consent. 
The isolation and expansion process was carried out 
as described previously [17]. Briefly, the cords were 
rinsed using phosphate-buffered saline (PBS) (Gibco™ 
Invitrogen, NY, USA), and cord blood was removed. The 
washed cords were cut into smaller pieces; transferred 
to a T25 culture flask (Corning, Tewksbury, MA, USA) 
containing Dulbecco’s Modified Eagle Medium (DMEM) 
(Sigma-Aldrich, Louis St., MO); supplemented with 10% 
fetal bovine serum (FBS) (Gibco™ Invitrogen, NY, USA), 
1% penicillin (100 U/mL)/streptomycin (100 µg/mL) 
(Gibco™ Invitrogen, NY, USA), and 0.25% amphotericin 
B (Gibco™ Invitrogen, NY, USA); and incubated at 
37°C in a humid atmosphere consisting of 5% CO2. The 
medium was renewed every 3 days. Non-adherent cells 
were removed by washing. After fibroblast-like cells 
appeared and reached 80% confluence (14 days), the 
cells were trypsinized and transferred into a new flask 
for further expansion. The cells derived from passage 5 
were used for the following experiments.
Flow cytometry analysis of MSCs
MSC-like surface markers were assessed 
by flow cytometry analysis at passage 5 according to 
the manufacturer’s instructions. MSC-like cells were 
trypsinized and pelleted by centrifugation at 1900 rpm 
for 8 min. The supernatant was removed, and pelleted 
cells were washed using PBS. Approximately 1 × 105 
detached cells were resuspended in 100 µl staining 
buffer (BD Bioscience, San Jose, CA, USA). For the 
staining of surface antigens, the cells were subsequently 
incubated using fluorescein isothiocyanate-, 
allophycocyanin (APC)-, peridinin-chlorophyll-protein 
(perCP)-CyTM5.5.1, and phycoerythrin (PE)-conjugated 
anti-human CD90, CD73, CD105, and Lin (CD45/CD34/
CD11b/CD19/HLA-DR) antibodies (BD Bioscience, 
San Jose, CA, USA) for 30 min at room temperature 
in the dark. In addition, an appropriate isotype-specific 
conjugated anti-IgG (BD Bioscience, San Jose, CA, 
USA) was used as the negative control. Unstained cells 
were also used to determine a threshold. Each sample 
was washed twice using PBS, and the analysis was 
performed using a BD Accuri C6 Plus flow cytometer 
(BD Bioscience, San Jose, CA, USA). A minimum of 1 
× 104 gated events on forward scatter and side scatter 
was recorded for each sample. Finally, post-acquisition 
analysis was conducted using BD Accuri C6 Plus 
software (BD Bioscience, San Jose, CA, USA).
In vitro osteogenic differentiation assay
The MSC-like cells were cultured at a density of 
1 × 104 cells/well in a 24-well plate with standard medium 
containing DMEM, 10% FBS, 1% penicillin (100 U/mL)/
streptomycin (100 µg/mL), and 0.25% amphotericin B. 
The cells were incubated at 37°C, 5% CO2, and ≥95% 
humidity. After 95% confluency was reached, the 
standard medium was replaced with an osteogenic 
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differentiation medium containing Human MesenCult™ 
Osteogenic Differentiation Basal Medium (Stem Cell 
Technologies, Singapore), supplemented with 20% 
Human MesenCult™ Osteogenic Differentiation 5X 
Supplement (Stem Cell Technologies, Singapore), and 
1% L-glutamine (Gibco™ Invitrogen, NY, USA). The 
differentiation medium was renewed every 3 days. 
After bone matrix formation occurred, osteogenic 
differentiation was visualized by adding 1 ml of 2% 
alizarin red solution (w/v) (pH 4.1–4.3). The cells were 
incubated at 37°C for 30 min, then washed 4 times in 
distilled water.
PBMCs Isolation and MSCs treatment in 
co-culture of PBMCs
Human PBMCs were isolated from 20 active 
SLE patients and 5 healthy controls at the same point 
using Ficoll-Paque (Sigma-Aldrich, Louis St., MO) 
density gradient centrifugation with specific informed 
consent. The separated buffy coat layer containing 
PBMCs was collected, washed, and pelleted by 
centrifugation at 1900 rpm for 8 min. Then, PBMCs 
were cultured in 2 ml of advanced RPMI 1640 culture 
medium (Gibco™ Invitrogen, NY, USA); supplemented 
with 10% FBS, 100 U/ml penicillin and streptomycin, and 
2 mM glutamine; and incubated at 37°C in a humidified 
atmosphere with 5% CO2. After 24 h of incubation, 
for the treatment group, PBMCs were cocultured with 
MSCs using a Corning Costar 0.4 µm Transwell cell 
culture plate in RPMI supplemented with 10% FBS, 1% 
penicillin-streptomycin, and 0.25% amphotericin B at 
an MSC to PBMC ratio of 1:1, 1:25, and 1:50 (T1, T2, 
and T3, respectively) for 72 h. On the other hand, for 
the negative and positive control groups, the isolated 
PBMCs from healthy and SLE patients, respectively, 
were cultured in another well plate with standard 
medium for 72 h.
Determination of IL-12 level
After 72 h, the coculture supernatants were 
analyzed using the Human IL-12/IL-23p40 Flex Set 
(560154, BD Biosciences, San Jose, CA, USA) 
according to the manufacturer’s instructions. Cell 
culture supernatants were collected and frozen at 
−80°C for cytometric bead array (CBA) measurement. 
After acquisition of sample data using BD Accuri C6 Plus 
Flow Cytometer (BD Biosciences, San Jose, CA, USA), 
the IL-12 level were calculated using the proprietary 
FCAP Version 1.0 analysis software (BD Biosciences, 
San Jose, CA, USA).
Data analysis
Values were presented as the mean ± SE. All 
calculations were carried out using SPSS 23.0 (IBM 
Corp., Armonk, NY, USA). Group comparisons were 
analyzed by ANOVA, followed by post hoc Fisher’s 
LSD. p < 0.05 was considered statistically significant.
Results
Isolation and differentiation of MSCs
MSC-like cells were isolated from UC and 
cultured based on their plastic adherent capability. The 
isolated cells were grown for 2 weeks in a monolayer 
until they reached 80% confluence and were employed 
for differentiation analysis after passage 5. The 
adherent cells cultured in standard medium showed 
fibroblastic morphology (spindle shaped) with multiple 
nucleoli, which is a typical characteristic of MSCs 
(Figure 1a). Furthermore, MSCs were also cultured 
in osteogenic differentiated medium to determine 
osteogenic differentiation capacity. After 20 days of 
incubation, the medium was replaced, and calcium 
deposition was visualized in red color after alizarin 
red solution administration (Figure 1b). The calcium 
deposition indicated that MSCs have the capability to 
differentiate into osteogenic lineage through forming 
the bone matrix, according to the main criteria defined 
by the International Society for Cellular Therapy (ISCT).
Figure 1: (a) Mesenchymal stem cells like characterized by their 
fibroblastic characteristic with spindle shape morphology; (b) and 
calcium deposition was shown in red color by alizarin red staining 
(200×)
a b
Characteristics of MSCs
At the end of the fifth passage expansion, 
MSC-like cells were trypsinized and passaged, and the 
surface antigens were analyzed using flow cytometry 
analysis. The specific profiles of MSC antigens are 
CD73, CD105, CD90, and negative for Lin (CD45/
CD34/CD11b/CD19/HLA-DR) antibodies in accordance 
with the ISCT criteria. The result showed that UC-MSCs 
expressed high levels of CD90 (99.9%), CD105 
(95.9%), and CD73 (99.2%) and lacked expression of 
Lin antibodies (2.0%) (Figure 2).
MSCs enhance IL-12 level after coculture 
with PBMCs
Finally, we measured the level of IL-12 after 
72 h of coculture between MSCs and SLE PBMCs. 
A - Basic Sciences Immunology
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We collected the coculture medium from treatment 
groups and the PBMC culture medium from negative 
and positive control groups. The CBA assay showed 
a significant increase in the Il-12 level in the T1 and 
T2 groups (p < 0.05). In T1 and T2, the IL-12 level 
was noted at 24.99 ± 5.35 and 27.77 ± 9.03 pg/mL, 
respectively (Figure 3).
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Figure 3: Mesenchymal stem cells (MSCs) decrease the IL-12 level 
in coculture between MSCs and peripheral blood mononuclear cells 
with SLE. After 72 h incubation, the cytometric bead array assay was 
used to determine the level of IL-12 in coculture system. The level 
of Il-12 was significantly decrease in T1 and T2 compared to control 
group. (*p < 0.05)
Discussion
MSCs’ capability to decrease the activation of 
the most proinflammatory-related Th cells has opened 
up a new understanding of SLE disease's. The MSCs 
capacity to suppress the proinflammatory condition 
in SLE depending on their responses to the type of 
immune cells, whether by inhibiting or modulating the 
immune cells [7], [8]. The one mechanisms of MSCs 
in controlling the inflammation is by suppressing 
the activated APC such as macrophage and DCs in 
releasing IL-12 to communicate with T-cell populations 
[10], [12]. 
However, the MSC-mediated 
immunosuppression to PBMCs derived from human 
SLE specifically in decreasing IL-12 levels remain 
incompletely understood. Here, we revealed the 
capacity of human MSCs to decrease the level of 
IL-12, one of the suppress cytokines involved in the 
differentiation of naive Th into Th-1 cells.
This study demonstrated that MSCs could 
inhibit the pro-inflammatory niche by suppressing IL-12 
significantly, a pro-inflammatory cytokine involved in 
robust Th1 expansion. We found that the IL-12 level was 
significantly decreased in human SLE PBMCs under 72 
hours of co-culture condition with MSCs at doses ratio 
of MSCs:PBMCs; 1:1 (high doses) and 1:25 (moderate 
doses): however, there is no differentiation of IL-12 
decrease among these doses. These data suggest 
that MSCs could hamper the robust pro-inflammatory 
condition of DCs and macrophage cells such as APCs 
under SLE conditions at only moderate doses. Under a 
pro-inflammatory niche, MSCs initially enhance TLR3 
expression [17] to activate NF-κβ and ERK pathway of 
MSCs type-1 however, along with the time, these MSCs 
were polarized into MSCs type-2 to express TLR4 and 
to produce IL-10 and TGF-β [18].
IL-10 is a major immunosuppressive cytokine 
involved in the maintenance of a balanced immune 
response [19]. In SLE conditions, the IL-10 level 
decreased due to the overactivation of IFN-γ-released 
Th1 and the depletion of Treg [20]. The massive release 
of IFN-γ could be involved in the positive feedback loop 
to activate APCs, such as macrophage and B cells, 
leading to the enhancement of several pro-inflammatory 
cytokine levels, including IL-12 [21]. MSCs could inhibit 
this robust inflammatory condition by expressing a 
high level of IL-10 [17,22]. IL-10 has a major role in 
limiting the extent of both innate and adaptive immune 
activation [23]. A previous study reported that IL-10 is 
one of the major negative regulators of TLR-induced 
IL-12 expression [24]. IL-10 also could suppress both 
Il12a and Il12b genes at the transcriptional level leading 
to the suppression of IL-12 level [25]. On the other 
hand, IL-12 can inhibit the expression of TGF-β-induced 
lineage-specific transcription factor FoxP3 to prevent 
the differentiation of Treg cells [26]. Hence, under high 
levels of IL-12 in SLE conditions, the production of 
Treg cells also could be inhibited, leading to the robust 
expansion of Th1 to result a massive inflammation. 
However, the MSCs could secrete a high level of TGF-β 
to result in the high generation of Treg cells to suppress 
Figure 2: Immunophenotyping analysis of mesenchymal stem cells which was positive for CD73, CD90, and CD105 and negative for Lin
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excessive anti-inflammatory cytokines [27], [28], [29].
These findings suggest that MSCs could regulate the 
inflammatory condition in human SLE by inhibiting IL-12 
expression. However, in our study, we did not explore 
the APCs, including DCs and macrophages as the cells 
producing IL-12 to differentiate naive Th into Th1 cells. 
Therefore, the mechanism MSCs in controlling the 
IL-12 in SLE disease through APCs pathways remains 
unclear. We also did not analyze the levels of IL-10 
and TGF-β as potent anti-inflammatory cytokines and 
major differentiation factors of Treg in controlling the 
inflammatory cells in SLE thus the mechanism of MSCs 
to decrease IL-12 in SLE disease should be further 
explored.
Conclusion
In summary, MSCs could inhibit the level of IL-12 
in PBMCs of human SLE. Therefore, the continuous 
naive Th12 differentiation into Th1 in SLE also reduced 
that is associated with the decrease of Th1-released 
IFNγ leading to the controlled the inflammation. This 
MSCs capacity could become a great and attractive 
therapy to control the inflammation of SLE.
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